Dorraya El-Ashry

TL;DR: RNA-seq and gene set enrichment analyses indicate that several compounds identified have favorable pharmacokinetic properties and show good tumor suppression in preclinical breast tumor models and may be suitable for further clinical evaluation in targeting aggressive breast cancers driven by FOXM1.

TL;DR: In this paper, the authors examined the metastatic propensity of heterotypic CAF-CTC clusters in orthotopic and tail vein xenograft mouse models of breast cancer.

TL;DR: A novel class of 1,1-diarylethylene FOXM1 inhibitory compounds are tested in suppressing TNBC cell migration, invasion, and metastasis using in vitro cell culture and in vivo tumor models, showing that these compounds inhibit the motility and invasiveness of TNBC MDA-MB-231 and DT28 cells, along with reducing the expression of important epithelial to mesenchymal transition (EMT) associated genes.

TL;DR: A summary of the major biomarker components often evaluated in liquid biopsy samples from patients with breast cancer, including circulating tumor cells, circulating cell-free tumor DNA, and cancer-associated plasma proteins is presented.

TL;DR: In this article, the presence of ESR1 mutations exclusively in distant, but not local recurrences, was found in ESR-1 mutant breast cancer cells, which exhibited non-canonical regulation of several metastatic pathways including secondary transactivation and de novo FOXA-driven chromatin remodeling.